A study on the utilization of canagliflozin in type 1 diabetes mellitus using real‐world data from four European countries

Documenti analoghi

• Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial
  di: Kathryn Cardoza, et al.
  Pubblicazione: (2024)
• Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis
  di: Daniel G. K. Rasmussen, et al.
  Pubblicazione: (2024)
• An SGLT2 inhibitor, canagliflozin, reduces blood glucose level in the renal capillaries and protects the capillary network in the diabetic rats
  di: Anqi Zhang, et al.
  Pubblicazione: (2025)
• Twenty‐four‐hour physical behaviour profiles across type 2 diabetes mellitus subtypes
  di: Joseph Henson, et al.
  Pubblicazione: (2024)
• The cost‐utility and budget impact analyses of Tirzepatide versus once‐weekly Semaglutide as add‐on therapy to metformin in patients with type 2 diabetes mellitus in China
  di: Sihua Wang, et al.
  Pubblicazione: (2025)